Is Segmental Ureterectomy Associated with Inferior Survival for Localized Upper-Tract Urothelial Carcinoma of the Ureter Compared to Radical Nephroureterectomy?

Simple Summary National cancer registry data showed that segmental ureterectomy is not associated with inferior survival compared to radical nephroureterectomy in upper-tract urothelial carcinoma patients. Segmental ureterectomy provides a valid surgical approach that does not meaningfully sacrifice survival outcomes within appropriately selected patients of upper urothelial carcinoma of the ureter. Given the potential renal functional preservation benefits, segmental ureterectomy should be considered for selected patients, especially if there is an increased probability of requiring adjuvant chemotherapy. Abstract Segmental ureterectomy (SU) is an alternative to radical nephroureterectomy (RNU) in the treatment of upper-tract urothelial carcinoma (UTUC) of the ureter. SU generally preserves renal function, at the expense of less intensive cancer control. We aim to assess whether SU is associated with inferior survival compared to RNU. Using the National Cancer Database (NCDB), we identified patients diagnosed with localized UTUC of the ureter between 2004–2015. We used a propensity-score-overlap-weighted (PSOW) multivariable survival model to compare survival following SU vs. RNU. PSOW-adjusted Kaplan–Meier curves were generated and we performed a non-inferiority test of overall survival. A population of 13,061 individuals with UTUC of the ureter receiving either SU or RNU was identified; of these, 9016 underwent RNU and 4045 SU. Factors associated with decreased likelihood of receiving SU were female gender (OR, 0.81; 95% CI, 0.75–0.88; p < 0.001), advanced clinical T stage (cT4) (OR, 0.51; 95% CI, 0.30–0.88; p = 0.015), and high-grade tumor (OR, 0.76; 95% CI, 0.67–0.86; p < 0.001). Age greater than 79 years was associated with increased probability of undergoing SU (OR, 1.18; 95% CI, 1.00–1.38; p = 0.047). There was no statistically significant difference in OS between SU and RNU (HR, 0.98; 95% CI, 0.93–1.04; p = 0.538). SU was not inferior to RNU in PSOW-adjusted Cox regression analysis (p < 0.001 for non-inferiority). In weighted cohorts of individuals with UTUC of the ureter, the use of SU was not associated with inferior survival compared to RNU. Urologists should continue to utilize SU in appropriately selected patients.

[1]  M. Sieberer,et al.  Neoadjuvant Chemotherapy before Nephroureterectomy in High-Risk Upper Tract Urothelial Cancer: A Systematic Review and Meta-Analysis , 2022, Cancers.

[2]  H. Lang,et al.  Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions , 2021, Cancers.

[3]  S. Lipsitz,et al.  Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. , 2021, Urologic oncology.

[4]  F. Saad,et al.  Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial Carcinoma. , 2020, European urology oncology.

[5]  Gregory J. Diorio,et al.  Nephroureterectomy vs. segmental ureterectomy of clinically localized, high-grade, urothelial carcinoma of the ureter: Practice patterns and outcomes. , 2020, Urologic oncology.

[6]  J. Donovan,et al.  Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial , 2020, The Lancet.

[7]  A. Levey,et al.  Chronic Kidney Disease and Kidney Cancer Surgery: New Perspectives. , 2020, The Journal of urology.

[8]  Steven L. Chang,et al.  Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis , 2019, World journal of urology.

[9]  Tao Xu,et al.  Segmental Ureterectomy is Acceptable for High-risk Ureteral Carcinoma Comparing to Radical Nephroureterectomy , 2019, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

[10]  R. Autorino,et al.  Segmental Ureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis of Comparative Studies. , 2019, Clinical genitourinary cancer.

[11]  H. Koike,et al.  Oncological and renal outcomes of segmental ureterectomy vs. radical nephroureterectomy for upper tract urothelial carcinoma. , 2018, Oncology letters.

[12]  Fan Li,et al.  Addressing Extreme Propensity Scores via the Overlap Weights , 2018, American journal of epidemiology.

[13]  A. Cole,et al.  Secondary data sources for health services research in urologic oncology. , 2017, Urologic oncology.

[14]  A. Cole,et al.  Secondary data analysis: techniques for comparing interventions and their limitations , 2017, Current opinion in urology.

[15]  S. Boorjian,et al.  Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease , 2017, World Journal of Urology.

[16]  M. Babjuk,et al.  European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. , 2015, European urology.

[17]  T. Klatte,et al.  Kidney-sparing surgery for upper tract urothelial cancer , 2015, Current opinion in urology.

[18]  P. Colin,et al.  Risk-adapted strategy for the kidney-sparing management of upper tract tumours , 2015, Nature Reviews Urology.

[19]  R. Thompson,et al.  Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma , 2014, BJU international.

[20]  M. Stifelman,et al.  Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. , 2010, European urology.

[21]  B. Lane,et al.  Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy , 2010, Cancer.

[22]  F. Montorsi,et al.  Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. , 2010, The Journal of urology.

[23]  P. Austin Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.

[24]  D. Vaughn Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium. , 2008, Cancer treatment reviews.

[25]  Stephen R Cole,et al.  Adjusted survival curves with inverse probability weights , 2004, Comput. Methods Programs Biomed..

[26]  L. Ellison,et al.  Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. , 2000, The Journal of urology.